Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Thiotepa 15 mg powder for concentrate for solution for infusion

Active Ingredient:
Company:  
MSN Laboratories Europe Ltd See contact details
ATC code: 
L01AC01
{info_black}
About Medicine
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine.
{info_black}
Last updated on emc: 26 Oct 2022

Below is a text only representation of the Patient Information Leaflet (ePIL).

The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on {phone} 0800 198 5000. The product code(s) for this leaflet is: PL 50805/0054.

Thiotepa 15 mg powder for concentrate for solution for infusion

Package leaflet: Information for the user

Thiotepa 15 mg powder for concentrate for solution for infusion

thiotepa

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor.
  • If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Thiotepa is and what it is used for
2. What you need to know before you use Thiotepa
3. How to use Thiotepa
4. Possible side effects
5. How to store Thiotepa
6. Contents of the pack and other information

1. What Thiotepa is and what it is used for

This medicine contains the active substance thiotepa, which belongs to a group of medicines called alkylating agents.

Thiotepa is used to prepare patients for bone marrow transplantation. It works by destroying bone marrow cells. This enables the transplantation of new bone marrow cells (haematopoietic progenitor cells), which in turn enable the body to produce healthy blood cells.

Thiotepa can be used in adults and children and adolescents.

2. What you need to know before you use Thiotepa
Do not use Thiotepa
  • if you are allergic to thiotepa or any of the other ingredients of this medicine (listed in section 6).
  • if you are pregnant or think you may be pregnant,
  • if you are breast-feeding,
  • if you are receiving yellow fever vaccination, live virus and bacterial vaccines

Warnings and precautions

Talk to your doctor before using Thiotepa and if you have:

  • liver or kidner problems,
  • heart or lung problems,
  • seizures/fits (epilepsy) or have had them in the past (if treated with phenytoin or fosphenytoin).

Because Thiotepa destroys bone marrow cells responsible for producing blood cells, regular blood tests will be taken during treatment to check your blood cell counts.

In order to prevent and manage infections, you will be given anti-infectives.

Thiotepa may cause another type of cancer in the future. Your doctor will discuss this risk with you.

Other medicines and Thiotepa

Tell your doctor if you are taking, have recently taken or might take any other medicines.

Pregnancy, breast-feeding and fertility

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, you must tell your doctor before you receive Thiotepa.

Both women and men using Thiotepa must use effective contraceptive methods during treatment.

It is not known whether this medicinal product is excreted in breast milk. As a precautionary measure, women must not breast-feed during treatment with Thiotepa.

Thiotepa can impair male and female fertility. Male patients should seek for sperm preservation before therapy is started and should not father a child while treated and during the year after cessation of treatment.

Driving and using machines

It is likely that certain adverse reactions of thiotepa like dizziness, headache and blurred vision could affect your ability to drive and use machines.

3. How to use Thiotepa

Your doctor will calculate the dose according to your body surface or weight and your disease.

How Thiotepa is given:

Thiotepa is administered by a qualified healthcare professional as an intravenous infusion (drip in a vein) after dilution of the individual vial. Each infusion will last 2-4 hours.

Frequency of administration:

You will receive your infusions every 12 or 24 hours. The duration of treatment can last up to 5 days. Frequency of administration and duration of treatment depend on your disease.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

The most serious side effects of Thiotepa therapy or the transplant procedure may include:

  • decrease in circulating blood cell counts (intended effect of the medicine to prepare you for your transplant infusion)
  • infection
  • liver disorders including blocking of a liver vein
  • the graft attacks your body (graft versus host disease)
  • respiratory complications

Your doctor will monitor your blood counts and liver enzymes regularly to detect and manage these events.

Side effects of Thiotepa may occur with certain frequencies, which are defined as follows:

Very common side effects (may affect more than 1 in 10 people)

  • increased susceptibility to infection
  • whole-body inflammatory state (sepsis)
  • decreased counts of white blood cells, platelets and red blood cells (anaemia)
  • the transplanted cells attack your body (graft versus host disease)
  • dizziness, headache, blurred vision
  • uncontrolled shaking of the body (convulsion)
  • sensation of tingling, pricking or numbness (paraesthesia)
  • partial loss of movement
  • cardiac arrest
  • nausea, vomiting, diarrhoea
  • inflammation of the mucosa of the mouth (mucositis)
  • irritated stomach, gullet, intestine
  • inflammation of the colon
  • anorexia, decreased appetite
  • high glucose in the blood
  • skin rash, itching, shedding
  • skin colour disorder (do not confuse with jaundice -see below)
  • redness of the skin (erythema)
  • hair loss
  • back and abdominal pain, pain
  • muscle and joint pain
  • abnormal electrical activity in the heart (arrhythmia)
  • inflammation of lung tissue
  • enlarged liver
  • altered organ function
  • blocking of a liver vein (Veno-Occlusive Disease, VOD)
  • yellowing of the skin and eyes (jaundice)
  • hearing impaired
  • lymphatic obstruction
  • high blood pressure
  • increased liver, renal and digestive enzymes
  • abnormal blood electrolytes
  • weight gain
  • fever, general weakness, chills
  • bleeding (haemorrhage)
  • nasal bleeding
  • general swelling due to fluid retention (oedema)
  • pain or inflammation at the injection site
  • eye infection (conjunctivitis)
  • decreased sperm cell count
  • vaginal bleeding
  • absence of menstrual periods (amenorrhea)
  • memory loss
  • delaying in weight and height increase
  • bladder disfunction
  • underproduction of testosterone
  • insufficient production of thyroid hormone
  • deficient activity of the pituitary gland
  • confusional state

Common side effects (may affect up to 1 in 10 people)

  • anxiety, confusion
  • abnormal bulging outward of one of the arteries in the brain (intracranial aneurysm)
  • creatinine elevated
  • allergic reactions
  • occlusion of a blood vessel (embolism)
  • heart rhythm disorder
  • heart inability
  • cardiovascular inability
  • oxygen deficiency
  • fluid accumulation in the lungs (pulmonary oedema)
  • pulmonary bleeding
  • respiratory arrest
  • blood in the urine (haematuria) and moderate renal insufficiency
  • inflammation of the urinary bladder
  • discomfort in urination and decrease in urine output (disuria and oliguria)
  • increase in the amount of nitrogen components in the blood stream (BUN increase)
  • cataract
  • inability of the liver
  • cerebral haemorrhage
  • cough
  • constipation and upset stomach
  • obstruction of the bowel
  • perforation of stomach
  • changes in muscle tone
  • gross lack of coordination of muscle movements
  • bruises due to a low platelet count
  • menopausal symptoms
  • cancer (second primary malignancies)
  • abnormal brain function
  • male and female infertility

Uncommon side effects (may affect up to 1 in 100 people)

  • inflammation and exfoliation of the skin (erythrodermic psoriasis)
  • delirium, nervousness, hallucination, agitation
  • gastrointestinal ulcer
  • inflammation of the muscular tissue of the heart (myocarditis)
  • abnormal heart condition (cardiomyopathy)

Not known: frequency cannot be estimated from the available data

  • increased blood pressure in the arteries (blood vessels) of the lungs (pulmonary arterial hypertension)
  • severe skin damage (e.g. severe lesions, bullae, etc.) potentially involving the full body surface which can be even life-threatening
  • damage to a component of the brain (the so called white matter) which can be even life-threatening (leukoencephalopathy).

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme. Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Thiotepa

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and vial label after EXP.

The expiry date refers to the last day of that month.

Store and transport refrigerated (2°C-8°C).

Do not freeze.

After reconstitution the product is stable for 8 hours when stored at 2°C -8°C.

After dilution the product is stable for 24 hours when stored at 2°C -8°C and for 4 hours when stored at 25°C. From a microbiological point of view, the product should be used immediately.

Any unused product or waste material should be disposed of in accordance with local requirements.

6. Contents of the pack and other information
What Thiotepa contains
  • The active substance is thiotepa. One vial contains 15 mg thiotepa. After reconstitution, each ml contains 10 mg thiotepa (10 mg/ml)
  • Thiotepa does not contain any other ingredients.

What Thiotepa looks like and contents of the pack

Thiotepa is a white lyophilized powder supplied in a glass vial containing 15 mg thiotepa.

Each carton contains 1 vial.

Marketing Authorisation Holder
Msn Laboratories Europe Limited
Invision House
Wilbury Way
Hitchin
SG4 0TY

Manufacturer
Pharmadox Healthcare Ltd
KW20A Kordin Industrial Park
Paola
PLA 3000
Malta

This leaflet was last revised in April 2022

MSN Laboratories Europe Ltd
Company image
Address
Devonshire, Business Centre, Works road, Letchworth Garden City, Herts, SG6 1GJ, UK
Telephone
020 3371 7158
Medical Information Direct Line
020 3371 7158
Medical Information e-mail
[email protected]
Customer Care direct line
07831 268 255
Stock Availability
07789 669 333